biostudies-literatureNewcomb LFNCI NIH HHS2084-2093https://www.ebi.ac.uk/biostudies/studies/S-EPMC11140579biostudies-literatureUnknown331(24)<h4>Importance</h4>Outcomes from protocol-directed active surveillance for favorable-risk prostate cancers are needed to support decision-making.<h4>Objective</h4>To characterize the long-term oncological outcomes of patients receiving active surveillance in a multicenter, protocol-directed cohort.<h4>Design, setting, and participants</h4>The Canary Prostate Active Surveillance Study (PASS) is a prospective cohort study initiated in 2008. A cohort of 2155 men with favorable-risk prostate cancer and no prior treatment were enrolled at 10 North American centers through August 2022.<h4>Exposure</h4>Active surveillance for prostate cancer.<h4>Main outcomes and measures</h4>Cumulative incidence of biopsy grade reclassification, treatment, metastasis, prostate cancer mortality, overall mortalityJAMALong-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer.PMC11140579U01 CA113913P30 CA015704P50 CA097186U01 CA224255McKenney JKZheng YBrooks JDLiu MDash ALin DWGleave MEWagner AACarroll PRde la Calle CMMartin FNewcomb LFZhu KLiss MAFilson CPNelson PSSchenk JMEllis WJTretiakova MSMorgan TMfalseLong-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer.<h4>Importance</h4>Outcomes from protocol-directed active surveillance for favorable-risk prostate cancers are needed to support decision-making.<h4>Objective</h4>To characterize the long-term oncological outcomes of patients receiving active surveillance in a multicenter, protocol-directed cohort.<h4>Design, setting, and participants</h4>The Canary Prostate Active Surveillance Study (PASS) is a prospective cohort study initiated in 2008. A cohort of 2155 men with favorable-risk prostate cancer and no prior treatment were enrolled at 10 North American centers through August 2022.<h4>Exposure</h4>Active surveillance for prostate cancer.<h4>Main outcomes and measures</h4>Cumulative incidence of biopsy grade reclassification, treatment, metastasis, prostate cancer mortality, overall mortality2024-01-01T00:00:00Z2024 Jun2026-06-02T03:48:44.301Z2026-04-14T03:12:29.32ZS-EPMC111405793881462410.1001/jama.2024.6695